Results 141 to 150 of about 150,695 (362)

Management of Diabetic Peripheral Neuropathy

The Korean Journal of Medicine, 2015
Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus. The prevalence of neuropathic pain is estimated to occur in about 30-50% of all diabetic patients. Clinical symptoms vary depending on the nerves affected, and may include both positive and negative symptoms. Many patients with DPN experience pain or discomfort, anxiety,
강명신 ( Myung Shin Kang ), 김종화 ( Chong Hwa Kim )   +1 more
openaire   +2 more sources

Mitochondrial Fusion Protein 2‐Modified Bone Marrow Mesenchymal Stem Cells Improved Hyperglycemia‐Induced Schwann Cell Injury via Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective High glucose damages rat Schwann cells (SCs), which is closely related to the dysfunction of mitochondria‐associated endoplasmic reticulum membranes (MAMs). Therefore, the present study aimed to investigate the protective effects and mechanisms of modified bone marrow mesenchymal stem cells (BMSCs) and mitochondrial fusion protein 2 (
Housheng Fu, Zhewen Ou, Fei Wang, Weifu Wang, Zhongyao Wang   +4 more
wiley   +1 more source

Diabetic peripheral neuropathy and neuromodulation techniques: a systematic review of progress and prospects

Neural Regeneration Research
Neuromodulation for diabetic peripheral neuropathy represents a significant area of interest in the management of chronic pain associated with this condition.
Rahul Mittal, Keelin McKenna, Grant Keith, Evan McKenna, Joana R. N. Lemos, Jeenu Mittal, Khemraj Hirani   +6 more
doaj   +1 more source

Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy

Scientific Reports, 2018
Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes. In this study, we employed a systems biology approach to identify DPN-related transcriptional pathways conserved across human and various murine models.
Brett A. McGregor, S. Eid, Amy E. Rumora, B. Murdock, K. Guo, Guillermo de Anda-Jáuregui, J. Porter, E. Feldman, J. Hur   +8 more
semanticscholar   +1 more source

Peripheral motor neuropathy in spontaneously diabetic WBN/Kob rats: a morphometric and electron microscopic study [PDF]

, 1989
Isao Narama, Isamu Kino
openalex   +1 more source

Proton pump inhibitor concomitant use to prevent oxaliplatin‐induced peripheral neuropathy: Clinical retrospective cohort study

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
Abstract Background Oxaliplatin‐induced peripheral neuropathy (OIPN) is a major clinical challenge because it leads to discontinuation of chemotherapy. Omeprazole, a proton pump inhibitor (PPI), has been shown to prevent OIPN in a rat model. Therefore, we aimed to test whether the concomitant use of a PPI reduces oxaliplatin discontinuation due to OIPN.
Keisuke Mine, Takehiro Kawashiri, Kohei Mori, Yusuke Mori, Haruna Ishida, Hibiki Kudamatsu, Shunsuke Fujita, Mayako Uchida, Takaaki Yamada, Nobuaki Egashira, Ichiro Ieiri, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe, Daisuke Kobayashi   +14 more
wiley   +1 more source

Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion. [PDF]

, 1987
F.W. Bertelsmann, J.J. Heimans, J C Van Rooy, H.F. Dankmeijer, S.L. Visser, E.A. van der Veen   +5 more
openalex   +1 more source

PDE5 inhibitors in diabetic peripheral neuropathy

International Journal of Clinical Practice, 2006
Peripheral neuropathy is the most common complication of diabetes. This paper reviews the case histories of five patients with diabetic peripheral neuropathy or severe peripheral vascular disease who reported improvement in their symptoms when treated with regular or daily dosing with phosphodiesterase type 5 inhibitors (PDE5Is).
openaire   +3 more sources

Computing Individual Risks based on Family History in Genetic Disease in the Presence of Competing Risks [PDF]

arXiv, 2017
When considering a genetic disease with variable age at onset (ex: diabetes , familial amyloid neuropathy, cancers, etc.), computing the individual risk of the disease based on family history (FH) is of critical interest both for clinicians and patients. Such a risk is very challenging to compute because: 1) the genotype X of the individual of interest
arxiv  

Advancing Sensory Modulation Wound Healing of Bionic Polymer Microneedle Patch

Sensory Neuroscience, EarlyView.
The complex etiology and pathogenesis of chronic wounds leading to a high rate of recurrence. Microneedle based transdermal drug delivery systems have emerged as new solutions in the field of drug delivery. Researchers developed polymer indwelling MN through a combined manufacturing strategy involving formwork replication and 3D transfer printing. With
Shana Zhang, Bingbing Gao
wiley   +1 more source